Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes

Table 3 Incidence of clinical events

Variables, n (%)	Overall	BP-SES	DP-EES	p value
Variables, n (%)	n = 141	n = 44	n = 100	p value
All cause death	7 (5.0)	2 (4.6)	5 (5.0)	0.906
Cardiac death	6 (4.2)	2 (4.6)	4 (4.0)	0.571
Myocardial infarction	2 (1.4)	2 (4.6)	0 (0)	0.585
Target lesion revascularization	7 (5.0)	5 (11.4)	2 (2.0)	0.003
Target vessel revascularization	9 (6.4)	5 (11.4)	4 (4.0)	0.595
Non-target vessel vascularization	7 (5.0)	2 (4.6)	5 (5.0)	0.837
Stent thrombosis	2 (1.4)	2 (4.6)	0 (0.0)	0.448
Major adverse cardiac event	12 (8.5)	6 (13.6)	6 (6.0)	0.878
Device-oriented clinical endpoint	12 (8.5)	6 (13.6)	6 (6.0)	0.035

BP-SES biodegradable polymer sirolimus-eluting stent, DP-EES durable polymer everolimus-eluting stent

ISSN: 1475-2840